Bayesian adaptive basket trial design using model averaging
- 20 May 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Biostatistics
- Vol. 22 (1) , 19-34
Abstract
Summary: In this article, we develop a Bayesian adaptive design methodology for oncology basket trials with binary endpoints using a Bayesian model averaging framework. Most existing methods seek to borrow information based on the degree of homogeneity of estimated response rates across all baskets. In reality, an investigational product may only demonstrate activity for a subset of baskets, and the degree of activity may vary across the subset. A key benefit of our Bayesian model averaging approach is that it explicitly accounts for the possibility that any subset of baskets may have similar activity and that some may not. Our proposed approach performs inference on the basket-specific response rates by averaging over the complete model space for the response rates, which can include thousands of models. We present results that demonstrate that this computationally feasible Bayesian approach performs favorably compared to existing state-of-the-art approaches, even when held to stringent requirements regarding false positive rates.Keywords
Funding Information
- National Institutes of Health
This publication has 19 references indexed in Scilit:
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsNew England Journal of Medicine, 2015
- Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic MedicineJournal of Clinical Oncology, 2015
- Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trialsClinical Trials, 2013
- All-Comers versus Enrichment Design Strategy in Phase II TrialsJournal of Thoracic Oncology, 2011
- On the efficiency of targeted clinical trialsStatistics in Medicine, 2005
- Evaluating the Efficiency of Targeted Designs for Randomized Clinical TrialsClinical Cancer Research, 2004
- Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypesStatistics in Medicine, 2003
- Reversible jump Markov chain Monte Carlo computation and Bayesian model determinationBiometrika, 1995
- Model Selection and Accounting for Model Uncertainty in Graphical Models Using Occam's WindowJournal of the American Statistical Association, 1994
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989